Clinical Trial Detail

NCT ID NCT03523572
Title Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

transitional cell carcinoma

breast cancer

Therapies

Nivolumab + Trastuzumab deruxtecan

Age Groups: senior adult

Additional content available in CKB BOOST